Herantis Appoints Tone Kvåle as Chief Financial Officer

Herantis Pharma Plc
Company release, [26 October 2020 at 9:35 a.m.] Eastern European Time

Herantis Pharma Plc
Company release 26 Oct 2020 at 9:35 am

Herantis Pharma Plc (“Herantis”), an innovative drug development company aiming to transform standard therapeutic approaches with its leading biologic and gene therapy, announces the appointment of Tone Kvåle as Chief Financial Officer and member of the management team, effective immediately.

Tone is a seasoned financial executive with a strong track record of more than 20 years of financial experience in the biotech and life sciences industry.  Most recently, Tone was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that held CFO roles at NorDiag, Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher.  In these roles she helped the companies raise over EUR 200m in financing, was involved in several trade sales, M&A and licensing deals, and was responsible for financial reporting under various reporting standards including US GAAP and IFRS.  Tone has a diploma in finance and administration from UiT The Arctic University of Norway, Harstad.

“We are delighted to welcome Tone to Herantis’ management team. She brings considerable financial acumen, public company biotech experience, and strategic skills that will be invaluable to the company.  Tone’s joining comes as Herantis enters its next chapter and progresses our pipeline of groundbreaking biological and gene therapy drugs in neurodegenerative and lymphatic diseases, a pivotal stage in the company’s development. We look forward to Tone being a key part of our future success,” commented Craig Cook, CEO.

Tone Kvåle, CFO, commented “I am excited to take on the CFO role at Herantis and very much look forward to working with the entire team, building on the company’s momentum, ambition, and strong biotech fundamentals.  I was drawn to Herantis because of its science promising to bring innovations that address critical gaps in the current standard of care for patients with these diseases.”

For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email:ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com
 

About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.